BR112022002060A2 - Síntese de escala de processo de um inibidor de calicreína de plasma - Google Patents

Síntese de escala de processo de um inibidor de calicreína de plasma

Info

Publication number
BR112022002060A2
BR112022002060A2 BR112022002060A BR112022002060A BR112022002060A2 BR 112022002060 A2 BR112022002060 A2 BR 112022002060A2 BR 112022002060 A BR112022002060 A BR 112022002060A BR 112022002060 A BR112022002060 A BR 112022002060A BR 112022002060 A2 BR112022002060 A2 BR 112022002060A2
Authority
BR
Brazil
Prior art keywords
process scale
plasma kallikrein
scale synthesis
kallikrein inhibitor
methods
Prior art date
Application number
BR112022002060A
Other languages
English (en)
Inventor
Yahya El-Kattan
S Babu Yarlagadda
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BR112022002060A2 publication Critical patent/BR112022002060A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Health & Medical Sciences (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

síntese de escala de processo de um inibidor de calicreína de plasma. a presente invenção refere-se a métodos de preparar o composto (i) e seus sais. os métodos de preparar o composto (i) são adequados para uso em escala de processo. (i)
BR112022002060A 2019-08-06 2020-08-05 Síntese de escala de processo de um inibidor de calicreína de plasma BR112022002060A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962883396P 2019-08-06 2019-08-06
PCT/US2020/044921 WO2021026182A1 (en) 2019-08-06 2020-08-05 Process-scale synthesis of a plasma kallikrein inhibitor

Publications (1)

Publication Number Publication Date
BR112022002060A2 true BR112022002060A2 (pt) 2022-06-07

Family

ID=74504082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002060A BR112022002060A2 (pt) 2019-08-06 2020-08-05 Síntese de escala de processo de um inibidor de calicreína de plasma

Country Status (20)

Country Link
US (1) US20220289683A1 (pt)
EP (1) EP4010320A4 (pt)
JP (1) JP2022543419A (pt)
KR (1) KR20220044276A (pt)
CN (1) CN114206839A (pt)
AR (1) AR119617A1 (pt)
AU (1) AU2020324422A1 (pt)
BR (1) BR112022002060A2 (pt)
CA (1) CA3149176A1 (pt)
CL (2) CL2022000264A1 (pt)
CO (1) CO2022002392A2 (pt)
CR (1) CR20220092A (pt)
EC (1) ECSP22016209A (pt)
IL (1) IL290113A (pt)
JO (1) JOP20220021A1 (pt)
MX (1) MX2022001608A (pt)
PE (1) PE20221009A1 (pt)
TW (1) TW202120481A (pt)
UY (1) UY38826A (pt)
WO (1) WO2021026182A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4180424A1 (en) 2014-03-07 2023-05-17 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
DE69110787T2 (de) 1990-02-28 1996-04-04 Medtronic Inc Intraluminale prothese mit wirkstoffeluierung.
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
WO2003016282A2 (en) * 2001-08-13 2003-02-27 E.I. Du Pont De Nemours And Company Substituted 1h-dihydropyrazoles, their preparation and use
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
EP2484676B1 (de) * 2008-12-18 2015-01-21 Bayer CropScience AG Tetrazolsubstituierte Anthranilsäureamide als Pestizide
EP4180424A1 (en) * 2014-03-07 2023-05-17 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors

Also Published As

Publication number Publication date
AR119617A1 (es) 2021-12-29
CO2022002392A2 (es) 2022-04-08
AU2020324422A1 (en) 2022-03-17
ECSP22016209A (es) 2022-06-30
CR20220092A (es) 2022-06-03
MX2022001608A (es) 2022-03-11
UY38826A (es) 2021-02-26
JOP20220021A1 (ar) 2023-01-30
CN114206839A (zh) 2022-03-18
EP4010320A1 (en) 2022-06-15
TW202120481A (zh) 2021-06-01
IL290113A (en) 2022-03-01
KR20220044276A (ko) 2022-04-07
WO2021026182A1 (en) 2021-02-11
PE20221009A1 (es) 2022-06-15
CL2022000264A1 (es) 2022-10-21
JP2022543419A (ja) 2022-10-12
CL2023000942A1 (es) 2023-11-24
US20220289683A1 (en) 2022-09-15
CA3149176A1 (en) 2021-02-11
EP4010320A4 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
BR112018011788A2 (pt) formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
CL2017002354A1 (es) Compuestos derivados de heteroarilos bicíclicos fusionados con actividad como inhibidores de phd.
BR122020014933B8 (pt) Compostos, composições farmacêuticas, benzenossulfonatos, forma a de ácido p-toluenossulfônico, forma b de ácido p-toluenssulfônico, forma i do ácido naftalenodissulfônico e forma ii do ácido naftalendissulfônico
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
BR112023003580A2 (pt) Compostos heterocíclicos
BR112019025028A2 (pt) Método para preparar um composto.
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
CL2021000903A1 (es) Nhibidores de ror gamma (solicitud divisional de la solicitud 217-2020
BR112015024109A2 (pt) derivados de ureia e seu uso como inibidores de proteína de ligação de ácidos graxos (fabp)
BR112023023527A2 (pt) Inibidores de nlrp3
BR112023022755A2 (pt) Composto cíclico possuindo efeito inibidor seletivo para kras, mas não para hras e nras
BR112014019585A8 (pt) Forma sólida de um composto, composição farmacêutica e cápsula em gel
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
BR112022002060A2 (pt) Síntese de escala de processo de um inibidor de calicreína de plasma
BR112018077390A2 (pt) sais cristalinos de peptídeo epoxicentona inibidor de imunoproteassoma
BR112023001053A2 (pt) Processo de clorantraniliprole aprimorado através do uso de um intermediário de cristal
BR112018071748A2 (pt) processo para a preparação de compostos herbicidas
BR112018071009A2 (pt) processo para a preparação de pamoato de pirvínio e formas cristalinas do mesmo
BR112019022265A2 (pt) silanos contendo benzotiazol, método para a preparação e uso dos mesmos
BR112021022347A8 (pt) Processos e intermediários para a preparação de um inibidor de btk
BR112016002724A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica e uso de composto
BR112022003186A2 (pt) Processo para preparar intermediário de inibidor de e-selectina